AstraZeneca says cancer drug Imfinzi improves survival chances in late-stage trial
Lung cancer patients treated with AstraZeneca’s immunotherapy Imfinzi pre- and post-surgery in a trial lived significantly longer without the disease progressing or recurring than those treated with chemotherapy, the drugmaker said on Thursday.The late…
Continue Reading